Title:Pharmaceutical Production of Anti-tumor and Immune-potentiating Enterococcus faecalis-2001 β-glucans: Enhanced Activity of Macrophage and Lymphocytes in Tumor-implanted Mice
VOLUME: 18 ISSUE: 8
Author(s):Yeun-Hwa Gu*, Hyunju Choi, Takenori Yamashita, Ki-Mun Kang, Masahiro Iwasa, Moon-Jo Lee, Kyoung Hae Lee and Cheorl-Ho Kim*
Affiliation:Department of Radiological Science, Faculty of Health Seience, Junshin Gakuen University, 1-1-1 Chikushigaoka, Minami-ku, Fukuoka 815-8510, 2Department of Biological Sciences, Sungkyunkwan University, Jangan-Gu, Suwon, Gyunggi-Do, 16419, Department of Radiological Science, Faculty of Health Seience, Suzuka University of Medical Science, Suzukashi, Mie 510-0293, Department of Therapeutic Radiology, Gyeongsang National University Hospital, Gyeongsang Institute of Health Sciences, Jinju, Nihon BRM Research Center, Akasaka Tokyu Bilding 9F, 2-14-3, Nagata- cho, Tsioda-ku, Tokyo 100-0014, Department of Herb Science, Dong-Eui Institute of Technology, 54, Yangji-ro, Busanjin-Gu, Busan 47230, Department of Food and Pharmaceutical Science, Dongnam Health University, Cheoncheon-Ro 74-Gil, Jangan-Gu, Suwon-Si, Gyeonggi-do, 16328, Department of Biological Sciences, Sungkyunkwan University, Jangan-Gu, Suwon, 16419
Keywords:Antioxidative potential, anti-tumor activity, Enterococcus faecalis, IFN-γ, immune-response, lymphocytes, NK
cells, TNF-α, β-glucan.
Abstract:Background: Enterococcus faecalis 2001 is a probiotic lactic acid bacterium and has been
used as a biological response modifier (BRM). From physiological limitation of bacterial preservation
in storage and safety, the live E. faecalis 2001 has been heat-treated and the BRM components containing
high level of β-glucan, named EF-2001, were prepared.
Method: The heat-treated EF-2001 has been examined for the antioxidative potential for radical scavenging
and anti-tumor activities as well as immune-enhancing response in mice. Lymphocyte versus polymorphonuclear
leukocyte ratio was increased in mice upon treatment with EF-2001. The number of lymphocytes
was increased in the EF-2001-treated group. In the mice bearing two different Ehrlich solid and
Sarcoma-180 carcinomas, the treatment with EF-2001 resulted in anti-tumor action. Tumor-suppressive
capacity upon treatment with EF-2001 was significantly increased compared to normal controls.
Results: During the time interval administration of 5 weeks between the priming and secondary administration
of EF-2001, the expression and production levels of TNF-α were also observed in the EF-
2001-administered mice. Additionally, anti-tumor activity examined with the intravenous administration
of EF 2001 with a 34 times interval was also observed, as the growth of Sarcoma180 cells was
clearly inhibited by the EF-2001.
Conclusion: From the results, it was suggested that the immune response is enhanced due to antioxidative
activity caused by the EF-2001 and anti-tumor activity by NK cells and TNF-α.
